Johnson & Johnson Stock News

Smith+Nephew cuts outlook, confirms failed merger talks with J&J's orthopaedics unit

SAN DIEGO--(BUSINESS WIRE)-- #PressRelease--Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific symposium (TCT 2026) that report positive survival and patient outcomes data when Impella™ heart pumps are used to support a patient's heart during and after high-risk percutaneous coronary interventio...

Who would have believed that the boring healthcare industry would be the hottest stock sector of 2026? Companies like Johnson & Johnson, Quest Diagnostics and UnitedHealth Group have long been known for producing steady results, driven by patient demand and government reimbursement.

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will hold an Enterprise Business Review for the investment community on Tuesday, December 8th, 2026. During the event, Company leaders will provide a detailed review of the Innovative Medicine and MedTech businesses, highlight how their pipelines are shaping the future of healthcare, and discuss the Company's long-term strategy...

BEERSE, BELGIUM, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study with first-line subcutaneous RYBREVANT®▼ (amivantamab) plus a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in patients with advanced recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) other than human papillomavirus (HP...

Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and resistance seen in 80 to 90 percent of HNSCC NEW BRUNSWICK, N.J., Oct. 25, 2026 /PRNewswire/ -- Johnson & Johnson (...

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed tumor-selective protein in prostate cancer cells Among patients with measurable disease in the 50 mg cohort, 75% achieved a complete or partial tumor response in the Phase 1 study 77% of patients achie...

BEERSE, BELGIUM , Oct. 24, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy), given for six months before and after surgery, with radical prostatectomy alone in patients with high-risk localised or locally advanced prostate canc...